Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab as Third-Line Treatment in Circulating Tumor DNA–Selected Metastatic Colorectal Cancer (ROMANCE Trial)
Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab as Third-Line Treatment in Circulating Tumor DNA–Selected Metastatic Colorectal Cancer (ROMANCE Trial). // Clinical Colorectal Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1533002826000721?dgcid=rss_sd_all
Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab as Third-Line Treatment in Circulating Tumor DNA–Selected Metastatic Colorectal Cancer (ROMANCE Trial). Clinical Colorectal Cancer. https://www.sciencedirect.com/science/article/pii/S1533002826000721?dgcid=rss_sd_all
“Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab as Third-Line Treatment in Circulating Tumor DNA–Selected Metastatic Colorectal Cancer (ROMANCE Trial).” Clinical Colorectal Cancer.
@article{article40525,
title = {Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab as Third-Line Treatment in Circulating Tumor DNA–Selected Metastatic Colorectal Cancer (ROMANCE Trial)},
journal = {Clinical Colorectal Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1533002826000721?dgcid=rss_sd_all}
}